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Abstract
There is growing interest in identifying surrogate tissues to identify epimutations in cancer patients since primary target
tissues are often difficult to obtain. Methylation patterns at imprinted loci are established during gametogenesis and post
fertilization and their alterations have been associated with elevated risk of cancer. Methylation at several imprinted
differentially methylated regions (GRB10 ICR, H19 ICR, KvDMR, SNRPN/SNURF ICR, IGF2 DMR0, and IGF2 DMR2) were analyzed
in DNA from leukocytes and mammary tissue (normal, benign diseases, or malignant tumors) from 87 women with and
without breast cancer (average age of cancer patients: 53; range: 31–77). Correlations between genomic variants and DNA
methylation at the studied loci could not be assessed, making it impossible to exclude such effects. Methylation levels
observed in leukocyte and mammary tissue DNA were close to the 50% expected for monoallellic methylation. While no
correlation was observed between leukocyte and mammary tissue DNA methylation for most of the analyzed imprinted
genes, Spearman’s correlations were statistically significant for IGF2 DMR0 and IGF2 DMR2, although absolute methylation
levels differed. Leukocyte DNA methylation levels of selected imprinted genes may therefore serve as surrogate markers of
DNA methylation in cancer tissue.
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Introduction
The epigenetic code allows cell function and phenotype to vary
without alteration of the DNA sequence. There is increasing
evidence that epigenetic mechanisms are involved in disease
processes, making epigenetic marks candidates for risk or early
detection markers. The tissue-specificity of epimutations represents
a challenge, however, since many target tissues cannot be routinely
collected in phenotypically healthy individuals. Surrogate tissues,
such as peripheral blood, buccal cells, saliva and urine, would
provide alternatives should they carry some of the same
epimutations as the target tissue.
Imprinted genes are monoallelically expressed according to
their parental origin [1], and many of them are candidates for
oncogenes or tumor suppressor genes [2]. Their expression is
largely controlled by specific DNA regions defined by distinct
methylation patterns. These regions are called imprinting control
regions (ICRs) if established in the germline, or somatic
differentially methylated regions (sDMRs) if established post-
fertilization [3]. Aberrant methylation at these sites is implicated in
a variety of childhood syndromes, such as the Beckwith-
Wiedemann, Prader-Willi, Angelman and Silver-Russell syn-
dromes [4,5,6]. Altered methylation of DMRs has also been
found in cancer cell lines and various primary tumor tissues
[7,8,9], and might precede carcinogenesis.
Matched samples of blood and mammary tissue from women
with and without invasive breast cancer were used to evaluate the
domains of regulation of imprinted genes, in order to understand
their variability and evaluate their potential as biomarkers of
cancer. The imprinted genes studied were: GRB10 ICR, IGF2
DMR0 and IGF2 DMR2, which are implicated in the insulin-like
growth factor signaling pathway that is often deregulated in breast
cancer [10,11]; H19 ICR, which is a potential tumor suppressor
gene [12]; KvDMR [13] and SNRPN/SNURF ICR [14], which are
known to be altered in different human cancers.
Materials and Methods
Study population
The Clinical Breast Care Project (CBCP) is a clinical and
research program that began enrolling patients in 2001. The
primary clinical arm of the CBCP is the Clinical Breast Care
Center at Walter Reed Army Medical Center. Additional
recruitment centers include the Joyce Murtha Breast Care Center
(Windber, PA, USA) and the Anne Arundel Medical Center
(Annapolis, MD, USA).
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following criteria: 1) over the age of 18 years; 2) mentally
competent and willing to provide informed consent; and 3)
presenting to the breast centers with evidence of possible breast
disease, for routine screening mammograms or elective reductive
mammoplasty. Patients were provided with layered consent forms
that included permission to gather samples of breast and
metastatic tissues as well as blood, and a description of primary
research uses of the samples. Once informed consent was granted,
the core questionnaire, with over 500 fields of information, was
completed with the help of a nurse case manager, and an extensive
pathology checklist was completed by a dedicated breast
pathologist.
Sample collection
For this study, clinical data, buffy coat and mammary tissue
DNA were obtained from 13 women with non-proliferative benign
conditions (no abnormalities, fat necrosis, or post-surgical chang-
es), 39 patients with proliferative benign diseases without atypia
(fibroadenoma (N=23), fibrocystic changes (N=10), stromal
fibrosis or others (N=6)), and 35 patients with invasive breast
cancer (infiltrating ductal carcinoma (IDCA) (N=31), mixed
ductal and lobular carcinoma (N=2), and other (N=2)). Women
with non-proliferative and proliferative benign conditions did not
significantly differ in DNA methylation at these loci (Figure S1).
Therefore both subgroups were collapsed into a single benign
breast disease category for further analyses.
Prior to treatment, up to 20 milliliters of blood was collected
into clot-activator and sodium heparin tubes for the isolation of
DNA, and the samples were processed immediately. Following
centrifugation, serum and/or plasma were separated from the
blood cells and all materials stored at 280uC. Genomic DNA was
isolated using Clotspin and Puregene DNA purification kits
according to manufacturer’s specifications (Qiagen, Valencia,
CA, USA) and diluted to a standard concentration of 25 ng/ul.
Tissue was collected from patients undergoing surgical procedures,
including lumpectomy, mastectomy, or reductive mammoplasty.
Within ten minutes of surgical removal, breast tissue was taken on
wet ice to the pathology laboratory where a licensed pathologist or
pathologist’s assistant performed routine pathology analyses (gross
characterization, margin status assessment and other indicators).
Excess tissue (cancerous and/or benign) was frozen for down-
stream research purposes. Genomic DNA was isolated from the
frozen tissue specimens after laser-microdissection of the region of
interest using the ASLMD system (Leica Microsystems, Wetzlar,
Germany) for invasive tissue, or after homogenization for benign
tissue. Microdissected or homogenized specimens were incubated
in proteinase K at 37uC overnight and then passed through
purification columns (Millipore, Billerica, MA, USA). Blood and
tissue samples were collected with approval from the Walter Reed
Army Medical Center Human Use Committee and Institutional
Review Board. All subjects enrolled in the CBCP voluntarily
agreed to participate and gave written informed consent. Aliquots
of approximately one microgram of DNA (less for tissue DNA)
were provided for this study, with the remaining DNA being used
for other research projects involving partners of the CBCP.
DNA Methylation Assays
Bisulfite conversion was performed in duplicate, on two
different days, using the EZ DNA Methylation Gold kit (Zymo
Research, Irvine, CA, USA) according to the manufacturer’s
Alternative Protocol 2. Two-hundred-and-fifty ng of DNA was
used for each duplicate conversion, and samples were eluted in
40 ul of elution buffer. PCR amplification of regions of interest
was performed using 3 microliters of bisulfite-converted DNA and
0.2 uM of each primer with the HotstarTaq plus Master Mix
(Qiagen, Valencia, CA, USA). Primer sequences and cycling
conditions are available in Figure S2. The primer sequences for
IGF2 DMR0 [15], IGF DMR2 [16], and H19 [17] have been
previously described. Each assay included a bisulfite conversion
control to verify full conversion of the DNA.
Methylation was analyzed by highly quantitative bisulfite
pyrosequencing [18] using the PyroMark Q24 system (Qiagen,
Valencia, CA, USA). Pyrophosphates released during the incor-
poration of individual nucleotides into the elongating DNA strand
are proportionally converted into light by a series of enzymatic
reactions, and the light is then detected by a camera and used to
calculate the percentage methylation at each CpG dinucleotide.
Values for each methylation assay were calculated by taking the
average methylation score across six CpG dinucleotides for GRB10
ICR and IGF2 DMR0, seven CpGs for IGF2 DMR2, eight for the
H19 and SNRPN/SNURF ICRs, and nine for KvDMR. The number
of assessed CpG sites was dependent upon the neighboring
sequence, and was determined by the PyroMark Assay Design 2.0
software (Qiagen, Valencia, CA, USA).
Each assay was validated by means of a series of standards of 0,
20, 40, 60, 80 and 100%-methylated DNA. The standards were
created in quadruplicate from whole genome amplified DNA,
representing 0% methylation, and DNA treated with CpG
methyltransferase M.SssI (New England Biolabs, Ipswich, MA,
USA), representing 100% methylation, which were mixed in
relative proportions to create the series (Figure S2).
Batch effect was avoided by replicating experiments from two
independent bisulfite treatments, with separate PCR and pyrose-
quencing experiments performed for each replicate.
The standard deviation for each population was calculated at
each CpG site and used to define a threshold to exclude replicates
with high variability, defined as a greater than two-standard-
deviation difference between replicates at multiple sites. Where
variability was high between replicates, repeats were performed
using two new samples of bisulfite-converted DNA until satisfac-
tory results were obtained or DNA stocks were exhausted. The
failure to determine the average methylation at one or more loci
was due to poor reproducibility of assays for samples of lower
quality, quantity, or incomplete bisulfite conversion.
Correlation between genetic variants and DNA methylation
could not be assessed due to insufficient quantities of DNA being
available for some of the samples following methylation analysis.
Statistical analyses
For each assay, the percent-methylation was calculated from the
average across the mean of the two replicates. Spearman
correlation coefficients between mean DNA methylation in
leukocytes and mammary tissues were calculated for each locus.
Missing values were excluded pairwise. All statistical significance
tests were two-sided, and an alpha-level of 0.05 was used.
Bonferroni adjustment was chosen due its common use and
stringency.
Results
A total of 87 women were included in this study: 35 with
invasive breast cancer and 52 with benign breast diseases (39 with
proliferative and 13 with non-proliferative benign breast condi-
tions). The characteristics of the women are summarized in
Table 1. Women with invasive breast cancer were older at tissue
collection and more likely to be postmenopausal than those with
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and were more likely to have a family history of breast cancer.
Methylation levels were successfully assessed in peripheral blood
samples from 87 women for GRB10 ICR, 81 women for H19 ICR,
85 women for KvDMR, 85 women for SNRPN/SNURF ICR,8 6
women for IGF2 DMR0, and 85 women for IGF2 DMR2.I n
mammary tissue, methylation levels were successfully assessed in
85 women for GRB10 ICR, 77 women for H19 ICR, 76 women for
KvDMR, 69 women for SNRPN/SNURF ICR, 69 women for IGF2
DMR0, and 65 women for IGF2 DMR2.
CpG methylation patterns at the loci
Using pyrosequencing, the percent-methylation was individually
determined at multiple CpG sites across each locus. Methylation
profiles were not uniform and demonstrated small inter-CpG site
differences (Figure S3). In the entire study population, the average
standard deviation across CpG sites for each locus were 4.7% for
GRB10 ICR, 5.9% for H19 ICR, 3.8% for KvDMR, 4.8% for
SNRPN/SNURF ICR, 10.2% for IGF2 DMR0, and 9.1% for IGF2
DMR2.
The average methylation at each locus demonstrated little
variation in women without breast cancer, with values close to the
expected 50% mark (Figure S3). Only IGF2 DMR2 showed a
methylation value lower than expected in mammary tissue DNA,
but this was not accompanied by a corresponding lower value in
leukocyte DNA (Figure S3). Where methylation values differed
from the expected 50% value, this was the result of changes across
all CpG sites at the locus, rather than large singular changes.
Methylation levels were more variable in mammary tissue than in
leukocytes (Fig. 1). Average methylation in leukocyte DNA ranged
from 36.5% to 55.3% at ICRs and from 39.5% to 69.7% at
sDMRs in women free of cancer, and between 38.7% and 53.3%
at ICRs and between 35.7% and 69.5% at sDMRs in women with
invasive breast cancer. In mammary tissue, DNA methylation
values ranged between 31.1% and 58.6% at ICRs and between
20.8% and 68.3% at sDMRs in women free of breast cancer, and
between 8.3% and 79.0% at ICRs and between 13.5% and 65.5%
at sDMRs in women with invasive breast cancer. Significant
correlation between somatic and germinal domains within the
same locus (H19/IGF2) was only observed in mammary tissues
between H19 ICR and IGF2 DMR0 (data not shown).
Correlation between DNA methylation levels in
leukocytes and mammary tissues
To establish whether variation of methylation in mammary
tissue is reflected in leukocyte DNA, correlations between tissue
and leukocyte DNA methylation were computed for each locus
(Table 2, Fig. 2). Only IGF2 DMR0 (rho=0.65, p,0.001) and
IGF2 DMR2 (rho=0.50, p=0.026) displayed a significant
correlation between tissue and blood in women with invasive
breast cancer but not in women free of breast cancer. Only the
IGF2 DMR0 correlation remained significant after correction for
multiple comparisons (Bonferroni-adjusted p=0.0036). Stratifica-
tion according to hormonal receptors status was plotted (Figure
S4), but correlations could not be calculated due to the small size
of subgroups.
Discussion
This study was focused on imprinted loci that are under the
control of differentially methylated domains [3] and have been
demonstrated to be frequently altered in cancer [19,20], but which
are expected to be conserved in healthy individuals. The
regulatory domains of these genes were investigated to determine
their variability and to evaluate their potential as biomarkers for
cancer in both blood and mammary tissue. Low interindividual
variation of methylation was observed at imprinted loci in
mammary tissue from women free of cancer, but considerable
variation was observed in women with invasive cancer. No
significant correlation was observed between the levels of DNA
methylation at the analyzed loci in mammary tissue and peripheral
blood in women with benign disease, but significant correlations
were identified in cancer patients for IGF2 DMR0 and IGF2
DMR2.
Methylation profiles at imprinted loci were relatively uniform
across CpG sites but displayed inter-CpG variation similar to those
observed by Ito at al. [15]. This observation suggests that
individual CpG dinucleotides do not adequately describe meth-
ylation at a gene locus and highlights the need for techniques other
than those based upon the use of restriction enzymes or single
nucleotide extension in order for more than one CpG site to be
analyzed per locus. These inter-CpG variations were higher in the
somatic DMRs (around 9%) compared to the germline ICRs
which demonstrated low variation (around 5%) regardless of the
parental origin of methylation. These results differ from the
observations of Woodfine et al. [16], who reported higher inter-
CpG variation in paternally methylated DMRs (e.g. H19 ICR,
Table 1. Characteristics of the 87 women included in this
study, drawn from the Clinical Breast Care Project.
Benign N=52 Invasive N=35
Age at tissue collection
(years)
Mean 40 53
Range [18–81] [31–77]
Race/Ethnicity (%)
1
White 32(61.5) 24 (68.6)
African American 16(30.8) 7 (20)
Other 4(7.7) 3 (8.6)
BMI (kg/m
2)
Mean 25.13 28.71
Range [17.14–36.99] [18.82–41.67]
Familial cancer history
1
st degree relative 3 3
2
nd degree relative 18 16
Age at 1
st period (years)
Mean 13 12
Range [9–17] [10–16]
Menopausal status
(N(%))
1
Premenopausal 40(76.9) 16(45.7)
Postmenopausal 3(5.8) 8(22.9)
Post-hysterectomy 4(7.7) 6(17.1)
Surgical menopause 3(5.8) 4(11.4)
Hormone Receptors Status
Estrogen Receptor Positive
only
20(57.1)
HER2 positive 9(25.7)
Triple negative 6(17.1)
1Percentages may not add up to 100 due to missing values.
doi:10.1371/journal.pone.0055896.t001
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dinucleotides at the H19 ICR locus were analyzed in this study and
that of Woodfine and colleagues [16], but using different primers,
this discrepancy may be assay-related. Alternatively, the small
number of samples in the previous study for inter-CpG variability
assessment (N=8) may have led to an overestimation of the inter-
CpG variation. The average methylation level at each CpG site
across the IGF2 DMR0 locus in breast tissue was similar to that
reported by Ito and colleagues [15].
There was significant correlation between methylation at the
IGF2 DMR0 and H19 ICR loci in mammary tissues. This is in
contrast to findings elsewhere in ovarian carcinomas [21] and
Wilms’ tumors [22], but are similar to observations with colorectal
cancers [23].
With the exception of IGF2 DMR2 in mammary tissue, the
average methylation values observed in the benign subgroup for
each imprinted locus were close to the expected 50% (representing
monoallelic methylation), suggesting that the methylation control
of these domains is well conserved. However, small but significant
differences in the methylation values were observed between blood
and tissue from the same individual, suggesting tissue-specificity as
previously demonstrated for expression [24] and for methylation
at non-imprinted loci [25].
Talens et al. [26] recently proposed the use of leukocyte DNA
for epigenetic epidemiology studies, since these samples are most
commonly available in existing biobanks. The authors highlighted
the need to assess each combination of locus, tissue and disease in
order to establish the potential use of leukocyte DNA as a
surrogate; however, in their study Talens and colleagues only
examined methylation in healthy individuals and found good
correlations between DNA methylation levels in leukocytes and
their tissue of interest (buccal cells) for imprinted loci (IGF2 and
KCNQ1OT1 which corresponds to KvDMR) and non-imprinted
genes (IGF2R, CRH, IL10, LEP, INSIGF, APOC1).
Recently, Cui et al. reported a significant correlation in IGF2
DMR0 methylation between colonic mucosa and peripheral blood
in healthy individuals, and altered DNA methylation in both
tissues among colorectal cancer patients [8]. However, Kaaks, et al.
did not observe an increased risk of colon cancer associated with
methylation changes at IGF2 DMR0 when using a more sensitive
and quantitative technique (short oligonucleotide mass analysis,
SOMA) than classical bisulfite sequencing [27]. Furthermore, Ito
et al. observed differences in IGF2 DMR0 methylation between
colorectal tumors and adjacent normal tissue but not in peripheral
blood of patients with and without colorectal cancer in an
unrelated population, using a threshold of #35% methylation to
classify hypomethylation. Due to the studies being conducted in
separate populations, the correlation between methylation in tissue
and blood could not be assessed [15].
Previous studies conducted elsewhere have suggested that SNPs
can affect the methylation status of a DNA region, increasing the
probability of inter-tissue positive correlation. Most reported
associations (95%) between SNPs and DNA methylation occur
with SNPs located within 149 kb of the CpG dinucleotides [28].
Figure 1. Comparisons of methylation values between blood and matching mammary tissue in different subgroups of patients.
Black circles correspond to the methylation value for an individual participant.
doi:10.1371/journal.pone.0055896.g001
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correlations [29], but only one, rs2239681, has been correlated
with methylation at IGF2 DMR0, and with a very low effect (beta
value=21.3%). This suggests that this SNP would have a low
impact on the results in this study, although the availability of such
data here would have increased the validity of the results by
removing the bias caused by genetic variants. This hypothesis
could not be assessed due to a lack of DNA, but it should be taken
into account for future studies.
A small number of studies have investigated IGF2 methylation
in breast cancer. Some early studies focused on allele-specific
expression of the gene, with McCann and colleagues having
observed biallelic expression of IGF2 in three of five informative
breast carcinomas [30], while Yballe, et al. identified loss of IGF2
imprinting in 2 of 17 breast tissues [31]. Elsewhere, Wu et al.
reported that 9 of 12 breast cancer samples displayed biallelic
expression of IGF2, suggesting a relaxation of imprinting [32]. Van
Roozendaal et al. observed biallelic expression of IGF2 in three of
four primary breast tumors examined, and also in the adjacent
histologically normal tissue [33], while Yun and colleagues in New
Zealand observed biallelic expression in 6 of 44 breast tumors and
also in 2 of 13 normal breast tissues [34]. Loss of imprinting of
IGF2 has also reported in half of 47 breast cancer tissues in one
study in China [35], and another study conducted in India
reported biallelic expression in 3 of 10 breast tumor samples [36].
Ito and colleagues reported lower IGF2 DMR0 methylation
levels in 13 of 22 mammary tumor samples compared with
histologically normal breast tissue from the same patient, with 7
tumor samples displaying less than 35% methylation [15].
However, IGF2 methylation levels did not correspond with loss
of imprinting. No association between IGF2 DMR0 methylation
and breast cancer incidence was found in prediagnostic blood
samples from another cohort [15], and Ito et al. therefore
concluded that the observed hypomethylation of IGF2 was
somatically acquired, rather than an innate epimutation.
Despite differences in the absolute methylation level between
the two tissues, statistically significant correlations were observed
for IGF2 DMR0 and IGF2 DMR2 between blood and tumor tissue
Figure 2. Comparisons between blood and mammary tissue DNA methylation. Axes correspond to percent-methylation observed in blood
and mammary tissue, respectively. Crosses correspond to non-cancerous cases, and circles to invasive cases.
doi:10.1371/journal.pone.0055896.g002
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ranking of individuals with respect to their methylation level is
largely preserved in peripheral blood samples from breast cancer
patients, but not among women free of breast cancer. This may
allow derivation of a calibration equation to predict levels of DNA
methylation in the tissue based upon those in the blood, with a
greater sample size and normal data distribution permitting the
use of parametric statistical models. If a calibration model of
adequate sensitivity and specificity can be derived, it could then be
used in populations for which only peripheral blood samples are
available to identify individuals with subclinical breast cancer.
Whether IGF2 may be a peripheral blood marker of breast cancer
remains to be established and requires further studies with larger
sample sizes. While no significant correlation was observed
between methylation in mammary tissue and leukocyte DNA for
the other imprinted loci studied, other epigenetic biomarkers of
breast cancer may be detectable in peripheral blood.
Supporting Information
Figure S1 Methylation distribution according to disease
subtype. White box plots correspond to benign conditions, grey
plots correspond to invasive breast cancer. 1: non-proliferative
conditions; 2: proliferative fibroadenomas; 3: proliferative fibro-
cystic changes; 4: proliferative stromal fibrosis and other benign
conditions; 5: Infiltrating Ductal Carcinoma (IDCA); 6: Other
invasive breast carcinomas. Bold lines represent the medians, the
boxes denote the 25th and 75th percentiles, the T bars correspond
to the minimum and maximum. Circles represent outliers.
(DOC)
Figure S2 A) Primer sequences and PCR conditions of the
different pyrosequencing assays. B) Methylation scales performed
using mix of whole genome amplified (WGA) DNA (expected 0%)
and MssI treated WGA DNA (expected 100%). Each point of the
scale was performed in quadruplicate. The line is the average
linear regression with its coefficient of determination (R
2).
(DOC)
Figure S3 Average methylation profile by CpG site for
each gene locus examined. Leukocyte (square and green
line) and mammary tissue (pink line and diamonds)
DNA from women free of breast cancer. Leukocyte (X and
blue line) and mammary tissue (plus and yellow line) DNA from
women with invasive breast cancer.
(DOC)
Figure S4 Comparisons of methylation values between
blood and matching mammary tissue in different
subgroups of patients stratified on hormonal receptors
status. Each black dot corresponds to the methylation value of an
individual participant.
(DOC)
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